Current cancer nanomedicines can only mitigate adverse effects but fail to enhance
therapeutic efficacies of anticancer drugs. Rational design of next‐generation cancer …

Platinum drugs comprise of almost 50% of all currently used anticancer drugs. They are now
widely used in the clinical therapy of various solid tumors, including ovarian, head and neck …

The significantly increased copper level in tumor tissues and serum indicates the close
association of copper ions with tumor development, making copper ions attractive targets in …

Now-a-days, the polysaccharides are extensively employed for the delivery of small-
molecule drugs ascribed to their excellent biocompatibility, biodegradability and …

Abstract Temozolomide (TMZ), an imidazotetrazine, is a second-generation DNA alkylating
agent used as a first-line treatment of glioblastoma multiforme (GBM). It was approved by …

Cancer continues to be one in all the leading reasons for death worldwide. The mean
cancer survival through standard therapeutic strategies has not been significantly improved …

Glioblastoma remains the most lethal form of brain cancer, where hybrid nanomaterials
biofunctionalized with polysaccharide peptides offer disruptive strategies relying on …

Paclitaxel (PTX) is an effective antineoplastic agent and shows potent antitumor activity
against a wide spectrum of cancers. Yet, the wide clinical use of PTX is limited by its poor …

Polymer-drug conjugation is an attractive approach for target delivering insoluble and highly
toxic drugs to tumor sites to overcome the side-effects caused by cancer chemotherapy. In …

Polymer–drug conjugates (PDCs) fabricated as nanoparticles have hogged the limelight in
cancer theranostics in the past decade. Many researchers have devoted to developing novel …